Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 32.0% in December

Evogene Ltd. (NASDAQ:EVGN) saw a large increase in short interest in December. As of December 31st, there was short interest totaling 65,630 shares, an increase of 32.0% from the December 15th total of 49,723 shares. Based on an average trading volume of 78,479 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.3% of the shares of the stock are short sold. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 78,479 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Investors Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. Jane Street Group LLC increased its position in Evogene Ltd. (NASDAQ:EVGN) by 58.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,732 shares of the biotechnology company’s stock after purchasing an additional 12,387 shares during the period. Jane Street Group LLC owned approximately 0.63% of Evogene worth $42,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.50.

Evogene Stock Performance

NASDAQ:EVGN opened at $1.05 on Friday. Evogene has a fifty-two week low of $0.93 and a fifty-two week high of $2.42. The company has a 50 day simple moving average of $1.10 and a two-hundred day simple moving average of $1.21. The company has a market capitalization of $5.64 million, a PE ratio of -2.10 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, November 20th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.10. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.65 million. Evogene had a negative net margin of 52.33% and a negative return on equity of 75.09%.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.